Skip to Content

Join the 'Hyperphosphatemia of Renal Failure' group to help and get support from people like you.

Hyperphosphatemia of Renal Failure News

A High Salt and Potassium Diet May Accelerate Chronic Kidney Disease

Posted 17 Sep 2015 by

THURSDAY, Sept. 17, 2015 – A diet high in sodium and potassium can make chronic kidney disease (CKD) worse, a new study claims. "These data warrant future clinical trials to test the effect of a moderate reduction in dietary sodium and potassium intake on CKD progression in patients with high dietary sodium or potassium intake," study leader Dr. Jiang He, from Tulane University, said in a news release from the American Society of Nephrology. "The findings could ultimately impact dietary recommendations for patients with CKD to slow disease progression," He added. It's estimated that 26 million people in the United States have chronic kidney disease, the researchers said. Chronic kidney disease can lead to kidney failure and also increases the risk for heart disease and early death, according to the study authors. For the study, the researchers tested urine samples from almost 4,000 ... Read more

Related support groups: Renal Failure, Klor-Con, Chronic Kidney Disease, Potassium Chloride, Sodium Chloride, Peritoneal dialysis, Klor-Con M20, Klor-Con M10, HalfLytely and Bisacodyl, K + Potassium, K-Dur, K-Tab, Slow-K, Klor-Con 10, Rhinaris, K-Dur 20, Micro-K 10, Micro-K, Hyper-Sal, Potassium Chloride/Sodium Chloride

Kidney Donors, Recipients Want to Know More About Each Other

Posted 18 Aug 2015 by

TUESDAY, Aug. 18, 2015 – Most living kidney donors and recipients would like to know more about each other's health before a transplant, a new study indicates. Currently, a transplant candidate must be told if the donor is at increased risk for hepatitis or HIV, but rules are unclear about what other health information can be shared. "Our finding that both donors and recipients support greater sharing of health and health-behavior information challenges the current approach to disclosure in organ transplantation," said study author Dr. Lainie Friedman Ross, of the University of Chicago. Researchers surveyed 76 kidney transplant recipients or candidates and 160 potential or actual donors. They found that 88 percent of the respondents said recipients should receive donors' general health information, and nearly four out of five said donors should be given recipients' general health ... Read more

Related support groups: Renal Failure, Renal Transplant, Peritoneal dialysis, Organ Transplant - Rejection Prophylaxis, Organ Transplant, Hyperphosphatemia of Renal Failure

Too Few Kidney Dialysis Patients Referred for Organ Transplant, Study Finds

Posted 11 Aug 2015 by

TUESDAY, Aug. 11, 2015 – Although a kidney transplant is considered the best hope for people struggling with end-stage renal disease, a new study conducted in Georgia found three-quarters of these patients weren't even evaluated for a possible transplant within their first year of dialysis. That finding flies in the face of U.S. regulations that require all dialysis centers to fully inform these patients about all available treatment options. Those options include kidney transplantation, a typically less expensive intervention than ongoing dialysis and one that also promises greater longevity and a better quality of life, the researchers noted. What's more, the team found a huge variation in statewide referral rates. Some dialysis centers failed to send even a single first-year patient for a transplant consultation, while others referred 75 percent of their new patients. It remains ... Read more

Related support groups: Renal Failure, Renal Transplant, Chronic Kidney Disease, Diabetic Kidney Disease, Peritoneal dialysis, Diabetic Nephropathy, Organ Transplant, Renal Osteodystrophy, Hyperphosphatemia of Renal Failure, Hypertensive Renal Disease, Anuria, Renal and Genitourinary Disorders

Kidney Problems Linked to Brain Disorders: Study

Posted 6 Aug 2015 by

THURSDAY, Aug. 6, 2015 – Kidney problems can increase the risk of brain disorders, a new study finds. The findings suggest that protecting kidney health may also benefit the brain, the researchers said. They studied data from more than 2,600 people in the Netherlands, and found that poor kidney function was strongly associated with decreased blood flow to the brain. They also saw an increased risk of stroke and memory and thinking problems (dementia) in people with kidney problems. The association was independent of known heart disease risk factors, the researchers said. The study was published Aug. 6 in the Journal of the American Society of Nephrology. "Our findings provide a possible explanation linking kidney disease to brain disease," Dr. M. Arfan Ikram, an assistant professor of neuroepidemiology at Erasmus University Medical Center in the Netherlands, said in a journal news ... Read more

Related support groups: Dementia, Renal Failure, Alzheimer's Disease, Kidney Infections, Chronic Kidney Disease, Diabetic Kidney Disease, Mild Cognitive Impairment, Peritoneal dialysis, Diabetic Nephropathy, Anemia Associated with Chronic Renal Failure, Polycystic Kidney Disease, Renal Osteodystrophy, Pyelonephritis, Hyperphosphatemia of Renal Failure, Renal Vein Thrombosis, Lewy Body Dementia, Renal and Genitourinary Disorders, Renovascular Hypertension

U.S. Dialysis Patients Increasingly Live in Poor Areas

Posted 24 Jun 2015 by

WEDNESDAY, June 24, 2015 – More than one-third of kidney dialysis patients in the United States live in poor neighborhoods, a study finds. Kidney dialysis rates in the United States are higher in poor neighborhoods, and they're increasing in those areas, the 15-year analysis shows. Dialysis is used to treat people with kidney failure. Researchers analyzed U.S. Centers for Medicare and Medicaid Services data to assess overall dialysis rates and those in poor areas, defined as having a a zip code where at least 20 percent of people live below the federal poverty line. The results showed that 27.4 percent of adults who began dialysis between 1995 and 2004 lived in poor neighborhoods, compared with about 11 percent of adults in the general population. Those percentages increased to 34 percent and 12.5 percent, respectively, between 2005 and 2010, said the researchers from Loyola University ... Read more

Related support groups: Renal Failure, Chronic Kidney Disease, Diabetic Kidney Disease, Peritoneal dialysis, Diabetic Nephropathy, Renal Osteodystrophy, Hyperphosphatemia of Renal Failure

Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate

Posted 17 Nov 2014 by

NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) – Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the trade name Auryxia (ferric citrate) for its FDA-approved ferric citrate. Auryxia, an iron-based phosphate binder, was approved by the FDA to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis in September 2014. Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are excited to receive FDA approval of the trade name Auryxia. We look forward to launching Auryxia in the U.S. at year end and to providing nephrologists with an effective phosphate binder for dialysis-dependent CKD patients." For more information about Auryxia, please visit About End Stage ... Read more

Related support groups: Hyperphosphatemia of Renal Failure, Ferric Citrate

Velphoro Receives US FDA Approval for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis

Posted 3 Dec 2013 by

November 28, 2013, Velphoro (sucroferric oxyhydroxide) has received US Food and Drug Administration (FDA) approval for the control of serum phosphorus levels in patients with Chronic Kidney Disease (CKD) on dialysis. Velphoro will be launched in the US by Fresenius Medical Care North America in 2014. Velphoro (previously known as PA21) is an iron-based, calcium-free, chewable phosphate binder. US approval was based on a pivotal Phase III study, which met its primary and secondary endpoints. The study demonstrated that Velphoro successfully controls hyperphosphatemia with fewer pills than sevelamer carbonate, the current standard of care in patients with CKD on dialysis1. The average daily dose to control hyperphosphatemia was 3.3 pills per day after 52 weeks. Velphoro was developed by Vifor Pharma. In 2011, all rights were transferred to Vifor Fresenius Medical Care Renal Pharma, a ... Read more

Related support groups: Hyperphosphatemia of Renal Failure

For Dialysis Patients, More Pills = Lower Quality of Life

Posted 13 May 2009 by

WEDNESDAY, May 13 – The more pills that kidney dialysis patients take, the more side effects they suffer and the worse their quality of life, a new study finds. Dialysis patients have to take more pills than most patients with other chronic diseases. In this study, researchers at the Los Angeles Biomedical Research Institute looked at the "pill burden" in 233 dialysis patients in the United States. The patients took an average of 19 pills a day, but 25 percent took more than 25 pills a day. Patients with a high pill burden reported poorer physical health. Phosphate binders, medications that control the level of phosphorous in the blood, accounted for about half of the daily pill burden. The study found that 62 percent of patients didn't take these medications as directed. The more phosphate binders patients were prescribed, the less likely they were to take the medications as directed, ... Read more

Related support groups: Hyperphosphatemia of Renal Failure

Ask a Question

Further Information

Related Condition Support Groups

Renal Failure

Related Drug Support Groups

Carafate, sucralfate, Renvela, Renagel, Fosrenol, magnesium carbonate, sevelamer, Velphoro, MagneBind 200, view more... MagneBind 300, Auryxia, Marblen, Dewees Carminative, ferric citrate, calcium carbonate / magnesium carbonate, lanthanum carbonate, Mag-Carb, sucroferric oxyhydroxide